ALEXION PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1992-01-01

Employees: 3.8K

Market Cap: -

Website: http://www.alexion.com

Clinical Trials

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Phase 2

Terminated

Conditions: Lysosomal Acid Lipase Deficiency

Interventions: Drug: Sebelipase Alfa

First Posted Date: 2014-07-18

Last Posted Date: 2019-11-18

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 10

Registration Number: NCT02193867

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

Phase 2

Completed

Conditions: Delayed Graft Function

Interventions: Drug: Eculizumab
Drug: Placebo

First Posted Date: 2014-05-22

Last Posted Date: 2018-12-17

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 288

Registration Number: NCT02145182

Locations: 🇧🇷
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Phase 2

Terminated

Conditions: Antiphospholipid (aPL)-Positive

Interventions: Biological: Study Drug- ALXN1007

First Posted Date: 2014-05-01

Last Posted Date: 2017-07-13

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 9

Registration Number: NCT02128269

Locations: 🇫🇷
Hopital Claude Huriez - CHU Lille, Lille, Nord, France
🇫🇷
Hôpital Cochin, Paris, France 75679, France
🇯🇵
Hokkaido University Hospital, Sapporo-shi, Hokkaido 060-8648, Japan

and more 6 locations

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Phase 2

Completed

Conditions: Lysosomal Acid Lipase Deficiency

Interventions: Drug: Sebelipase Alfa

First Posted Date: 2014-04-14

Last Posted Date: 2019-12-04

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 31

Registration Number: NCT02112994

Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

Completed

Conditions: Hypophosphatasia (HPP)

First Posted Date: 2014-04-04

Last Posted Date: 2019-04-01

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 32

Registration Number: NCT02104219

Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging

Completed

Conditions: MPS IIIB (Sanfilippo B Syndrome)

First Posted Date: 2014-03-18

Last Posted Date: 2016-06-27

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 5

Registration Number: NCT02090179

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Phase 3

Completed

Conditions: Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica

Interventions: Biological: eculizumab

First Posted Date: 2013-12-06

Last Posted Date: 2022-08-23

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 119

Registration Number: NCT02003144

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
The Research Center of Southern California, Oceanside, California, United States
🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

and more 66 locations

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Phase 3

Completed

Conditions: Refractory Generalized Myasthenia Gravis

Interventions: Biological: Eculizumab
Drug: Placebo

First Posted Date: 2013-11-28

Last Posted Date: 2019-07-16

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 125

Registration Number: NCT01997229

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
University of California San Francisco-Fresno, Fresno, California, United States
🇺🇸
University of California-Irvine, Orange, California, United States

and more 111 locations

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Phase 1

Completed

Conditions: Follicular Lymphoma (FL/Indolent NHL)
Aggressive NHL (a NHL)
B-cell Non Hodgkin Lymphoma (NHL)
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
T-cell Lymphoma (PTCL and CTCL)

Interventions: Drug: Cerdulatinib
Biological: Rituximab

First Posted Date: 2013-11-25

Last Posted Date: 2022-04-05

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 260

Registration Number: NCT01994382

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Phase 3

Terminated

Conditions: Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica

Interventions: Drug: Eculizumab
Drug: Placebo

First Posted Date: 2013-07-04

Last Posted Date: 2019-06-26

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 143

Registration Number: NCT01892345

Locations: 🇺🇸
John Hopkins University School of Medicine, Baltimore, Maryland, United States
🇦🇺
University of Sydney, Brain and Mind Center, Camperdown, New South Wales, Australia
🇦🇺
St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

and more 67 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy